PMID- 1362159
OWN - NLM
STAT- MEDLINE
DCOM- 19930205
LR  - 20190623
IS  - 0014-2999 (Print)
IS  - 0014-2999 (Linking)
VI  - 223
IP  - 1
DP  - 1992 Nov 13
TI  - 5-HT2 receptors exert a state-dependent regulation of dopaminergic function: 
      studies with MDL 100,907 and the amphetamine analogue, 
      3,4-methylenedioxymethamphetamine.
PG  - 65-74
AB  - The highly selective 5-HT2 receptor antagonist, MDL 100,907, was used to explore 
      the role of serotonin in the stimulation of dopaminergic function produced by the 
      amphetamine analogue 3,4-methylenedioxymethamphetamine (MDMA). MDL 100,907 
      blocked MDMA-stimulated dopamine synthesis in vivo without affecting basal 
      synthesis. The long-term deficits in 5-HT concentrations believed to be a 
      consequence of MDMA-induced dopamine release were also blocked by MDL 100,907 
      over the same dose range. In vivo microdialysis confirmed that 5-HT2 receptor 
      blockade with MDL 100,907 attenuated MDMA-induced increases in extracellular 
      concentrations of striatal dopamine. In contrast to its effect on MDMA-induced 
      synthesis, MDL 100,907 did not alter dopamine synthesis stimulated by haloperidol 
      or reserpine. In vivo dopamine release produced by haloperidol was also 
      unaffected by MDL 100,907. The results suggest a permissive role for 5-HT2 
      receptors in the activation of the dopamine system which occurs during states of 
      high serotonergic activity or during conditions of elevated dopamine efflux with 
      high D2 receptor occupancy.
FAU - Schmidt, C J
AU  - Schmidt CJ
AD  - Marion Merrel Dow Research Institute, Cincinnati OH 45215.
FAU - Fadayel, G M
AU  - Fadayel GM
FAU - Sullivan, C K
AU  - Sullivan CK
FAU - Taylor, V L
AU  - Taylor VL
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Fluorobenzenes)
RN  - 0 (Piperidines)
RN  - 0 (Serotonin Antagonists)
RN  - 102-32-9 (3,4-Dihydroxyphenylacetic Acid)
RN  - 4764-17-4 (3,4-Methylenedioxyamphetamine)
RN  - 8B1QWR724A (Reserpine)
RN  - EW71EE171J (volinanserin)
RN  - J6292F8L3D (Haloperidol)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - VTD58H1Z2X (Dopamine)
RN  - X77S6GMS36 (Homovanillic Acid)
SB  - IM
MH  - 3,4-Dihydroxyphenylacetic Acid/metabolism
MH  - 3,4-Methylenedioxyamphetamine/*analogs & derivatives/pharmacology
MH  - Animals
MH  - Brain Chemistry/drug effects
MH  - Dialysis
MH  - Dopamine/metabolism/*physiology
MH  - Fluorobenzenes/*pharmacology
MH  - Haloperidol/pharmacology
MH  - Homovanillic Acid/metabolism
MH  - Male
MH  - N-Methyl-3,4-methylenedioxyamphetamine
MH  - Piperidines/*pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Reserpine/pharmacology
MH  - *Serotonin Antagonists
EDAT- 1992/11/13 00:00
MHDA- 1992/11/13 00:01
CRDT- 1992/11/13 00:00
PHST- 1992/11/13 00:00 [pubmed]
PHST- 1992/11/13 00:01 [medline]
PHST- 1992/11/13 00:00 [entrez]
AID - 0014-2999(92)90819-P [pii]
AID - 10.1016/0014-2999(92)90819-p [doi]
PST - ppublish
SO  - Eur J Pharmacol. 1992 Nov 13;223(1):65-74. doi: 10.1016/0014-2999(92)90819-p.